KindlyMD, Inc. (NASDAQ:NAKA) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on KindlyMD, with one sell, one hold and three buy recommendations. The average 12-month price target is $22.33.
• CEO David F. Bailey purchased 104,833 shares at an average price of $4.84, while insiders bought 191,448 shares worth nearly $993,000 over the past three months; insiders own 24.49% of the company.
• KindlyMD reported a quarterly loss of $0.38 per share on $2.68 million in revenue, with sharply negative profitability metrics. Shares opened at $4.94, compared with a 52-week range of $3.33 to $624.00.

KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) has been given an average rating of "Hold" by the five brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $22.3333.

NAKA has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of KindlyMD to a "sell" rating in a research note on Saturday, May 23rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of KindlyMD in a research note on Friday, August 7th. Finally, TD Cowen boosted their price objective on shares of KindlyMD from $1.00 to $17.00 and gave the stock a "buy" rating in a report on Monday, July 27th.

Insider Transactions at KindlyMD

In related news, CEO David F. Bailey purchased 104,833 shares of KindlyMD stock in a transaction dated Wednesday, May 27th. The stock was bought at an average cost of $4.84 per share, for a total transaction of $507,391.72. Following the transaction, the chief executive officer owned 3,120,361 shares in the company, valued at approximately $15,102,547.24. The trade was a 3.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have bought 191,448 shares of company stock valued at $992,908 over the last three months. Company insiders own 24.49% of the company's stock.

Institutional Investors Weigh In On KindlyMD

A number of institutional investors and hedge funds have recently modified their holdings of the company. Osaic Holdings Inc. purchased a new position in KindlyMD in the 2nd quarter valued at approximately $215,000. Geode Capital Management LLC boosted its position in KindlyMD by 76.2% during the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company's stock worth $484,000 after purchasing an additional 8,386 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in KindlyMD by 1,638.4% during the third quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company's stock worth $827,000 after purchasing an additional 31,245 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in KindlyMD in the third quarter valued at $1,007,000. Finally, Vident Advisory LLC acquired a new stake in KindlyMD in the third quarter valued at $2,092,000.

KindlyMD Price Performance

Shares of NAKA stock opened at $4.94 on Thursday. The business's fifty day moving average price is $4.37 and its 200 day moving average price is $7.65. KindlyMD has a 1-year low of $3.33 and a 1-year high of $624.00. The firm has a market capitalization of $85.97 million, a PE ratio of -0.11 and a beta of 15.95.

KindlyMD (NASDAQ:NAKA - Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.38) EPS for the quarter. The business had revenue of $2.68 million during the quarter. KindlyMD had a negative net margin of 7,397.12% and a negative return on equity of 81.32%. Equities research analysts expect that KindlyMD will post -16.8 earnings per share for the current fiscal year.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source